Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. Its clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia and IgA nephropathy.

Company Growth (employees)
South San Francisco, US
Size (employees)
77 (est)
Rigel Pharmaceuticals was founded in 1996 and is headquartered in South San Francisco, US

Key People at Rigel Pharmaceuticals

Raul R. Rodriguez

Raul R. Rodriguez

President & CEO
Frank Torti

Frank Torti

Elliott B. Grossbard

Elliott B. Grossbard


Rigel Pharmaceuticals Office Locations

Rigel Pharmaceuticals has an office in South San Francisco
South San Francisco, US (HQ)
1180 Veterans Boulevard

Rigel Pharmaceuticals Data and Metrics

Rigel Pharmaceuticals Financial Metrics


Net income (Q1, 2017)

(15.3 m)

EBIT (Q1, 2017)

(16.2 m)

Market capitalization (21-Sep-2017)

270.4 m

Cash (31-Mar-2017)

40.1 m
Rigel Pharmaceuticals's current market capitalization is $270.4 m.
USDFY, 2016

R&D expense

63.4 m

General and administrative expense

20.9 m

Operating expense total

84.4 m


(69.7 m)
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

20.1 m16.2 m15.1 m15.5 m18.2 m17.5 m16.2 m12.4 m

General and administrative expense

5.4 m4.9 m4.1 m4.3 m4.4 m4.8 m4.6 m7.4 m

Operating expense total

25.5 m21 m19.2 m19.8 m22.6 m22.2 m20.7 m19.8 m


(25.5 m)(21 m)(14 m)(6.8 m)(17.6 m)(13.6 m)(22.7 m)(16.2 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


20.9 m15.2 m43.5 m17.6 m

Accounts Receivable

5.8 m5.8 m203 k

Current Assets

220.1 m150.5 m129 m76.2 m


4.5 m2.5 m1.6 m1.2 m
USDQ2, 2014Q3, 2014Q1, 2017


23.9 m12.8 m40.1 m

Current Assets

177.5 m158.9 m99.5 m


3.4 m2.9 m1.1 m

Total Assets

182.4 m163.2 m101.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(89 m)(90.9 m)(51.5 m)(69.2 m)

Depreciation and Amortization

2.6 m2.4 m1.4 m941 k

Accounts Receivable

(5.8 m)(5.8 m)5.5 m203 k


1.9 m722 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(47.7 m)(68.6 m)(13.9 m)(6.7 m)(17.5 m)(13.5 m)(22.6 m)(15.3 m)

Depreciation and Amortization

1.3 m1.9 m126 k

Accounts Receivable

5.8 m5.8 m106 k350 k163 k195 k95 k203 k8 k

Accounts Payable

(2 m)(2.9 m)1.1 m1.1 m689 k2.4 m1.5 m1.5 m(4.4 m)
Y, 2017

Financial Leverage

1.2 x
Show all financial metrics

Rigel Pharmaceuticals Market Value History

Traffic Overview of Rigel Pharmaceuticals

Rigel Pharmaceuticals Online and Social Media Presence

Rigel Pharmaceuticals Company Life and Culture

You may also be interested in